查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1460201

肺炎治療市場 - 全球產業分析、規模、佔有率、成長、趨勢和預測，2023-2031

Pneumonia Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 162 Pages | 商品交期: 2-10個工作天內

價格

肺炎治療市場 - 報告範圍

TMR 關於全球肺炎治療市場的報告研究了過去以及當前的成長趨勢和機會，以獲得 2023 年至 2031 年預測期內市場指標的寶貴見解。該報告提供了全球肺炎治療市場的收入2017-2031年期間，考慮2023年為基準年，2031年為預測年。報告中也提供了2023年至2031年全球肺炎治療市場的年複合成長率（CAGR %）。

該報告是經過廣泛研究後編寫的。初級研究涉及大部分研究工作，其中分析師對關鍵意見領袖、行業領導者和輿論製造者進行了採訪。二次研究涉及參考主要參與者的產品文獻、年度報告、新聞稿和相關文件，以了解肺炎治療市場。

市場概況
2022年市場價​​值 30 億美元
2031 年市場價值 57 億美元
CAGR 7.3%

該報告深入探討了全球肺炎治療市場的競爭格局。全球肺炎治療市場的主要參與者已經確定，並且每位參與者都根據不同的屬性進行了分析。公司概況、財務狀況、最新發展和 SWOT 是本報告中介紹的全球肺炎治療市場參與者的屬性。

目錄

第1章：前言

第 2 章：假設與研究方法

第 3 章：執行摘要：全球市場

第 4 章：市場概述

  • 介紹
  • 概述
  • 市場動態
  • 2017-2031 年全球市場分析與預測

第 5 章：關鍵見解

  • 重要產業活動
  • 監管場景
  • 按地區/全球分類的疾病發生率和盛行率
  • COVID-19 影響分析

第 6 章：全球市場分析與預測：按類型

  • 簡介與定義
  • 主要發現/進展
  • 2017-2031 年按類型分類的市場價值預測
    • 細菌性肺炎
    • 病毒性肺炎
    • 黴菌性肺炎
  • 按類型分類的市場吸引力

第 7 章：全球市場分析與預測：依年齡段

  • 簡介與定義
  • 主要發現/進展
  • 2017-2031 年各年齡層市場價值預測
    • 孩子們
    • 成人
    • 老年科
  • 按年齡層分類的市場吸引力

第 8 章：全球市場分析與預測：按管理途徑

  • 簡介與定義
  • 主要發現/進展
  • 2017-2031 年按給藥途徑分類的市場價值預測
    • 口服
    • 注射用
    • 其他
  • 按給藥途徑分類的市場吸引力

第 9 章：全球市場分析與預測：按藥物類別

  • 簡介與定義
  • 主要發現/進展
  • 2017-2031 年按藥物類別分類的市場價值預測
    • 抗生素
    • 抗病毒藥物
    • 抗真菌藥物
    • 皮質類固醇
    • 其他（非類固醇抗發炎藥、止咳藥等）
  • 按藥物類別分類的市場吸引力

第 10 章：全球市場分析與預測：按配銷通路

  • 簡介與定義
  • 主要發現/進展
  • 2017-2031 年按配銷通路分類的市場價值預測
    • 醫院藥房
    • 零售藥局
    • 網路藥局
  • 按配銷通路分類的市場吸引力

第 11 章：全球市場分析與預測：按地區

  • 主要發現
  • 各地區市場價值預測
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 按國家/地區分類的市場吸引力

第 12 章：北美市場分析與預測

第 13 章：歐洲市場分析與預測

第 14 章：亞太市場分析與預測

第 15 章：拉丁美洲市場分析與預測

第 16 章：中東和非洲市場分析與預測

第17章：競爭格局

  • 市場參與者 - 競爭矩陣（依公司層級和規模）
  • 公司市佔率分析 (2022)
  • 公司簡介
    • AstraZeneca
    • Novartis AG
    • AbbVie Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Sumitomo Pharma Co., Ltd.
    • Pfizer Inc.
    • Sanofi
    • Lupin Pharmaceuticals, Inc.
    • Wockhardt Ltd.
    • Innoviva, Inc.
Product Code: TMRGL36068

Pneumonia Therapeutics Market - Scope of Report

TMR's report on the global pneumonia therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global pneumonia therapeutics market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global pneumonia therapeutics market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the pneumonia therapeutics market.

Market Snapshot
Market Value in 2022US$ 3 Bn
Market Value in 2031US$ 5.7 Bn
CAGR7.3%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global pneumonia therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global pneumonia therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global pneumonia therapeutics market.

The report delves into the competitive landscape of the global pneumonia therapeutics market. Key players operating in the global pneumonia therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global pneumonia therapeutics market profiled in this report.

Key Questions Answered in Global pneumonia therapeutics Market Report:

  • What is the sales/revenue generated by pneumonia therapeutics across all regions during the forecast period?
  • What are the opportunities in the global pneumonia therapeutics market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Pneumonia Therapeutics Market - Research Objectives and Research Approach

The comprehensive report on the global pneumonia therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global pneumonia therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global pneumonia therapeutics market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Pneumonia Therapeutics Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Pneumonia Therapeutics Market Analysis and Forecasts, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Key Industry Events
  • 5.2. Regulatory Scenario
  • 5.3. Disease Incidence & Prevalence Rate by Region/globally
  • 5.4. COVID-19 Impact Analysis

6. Global Pneumonia Therapeutics Market Analysis and Forecasts, By Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast By Type, 2017-2031
    • 6.3.1. Bacterial Pneumonia
    • 6.3.2. Viral Pneumonia
    • 6.3.3. Fungal Pneumonia
  • 6.4. Market Attractiveness By Type

7. Global Pneumonia Therapeutics Market Analysis and Forecasts, By Age Group

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast By Age Group, 2017-2031
    • 7.3.1. Children
    • 7.3.2. Adult
    • 7.3.3. Geriatric
  • 7.4. Market Attractiveness By Age Group

8. Global Pneumonia Therapeutics Market Analysis and Forecasts, By Route of Administration

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast By Route of Administration, 2017-2031
    • 8.3.1. Oral
    • 8.3.2. Parenteral
    • 8.3.3. Others
  • 8.4. Market Attractiveness By Route of Administration

9. Global Pneumonia Therapeutics Market Analysis and Forecasts, By Drug Class

  • 9.1. Introduction & Definition
  • 9.2. Key Findings / Developments
  • 9.3. Market Value Forecast By Drug Class, 2017-2031
    • 9.3.1. Antibiotics
    • 9.3.2. Antiviral Drugs
    • 9.3.3. Antifungal Drugs
    • 9.3.4. Corticosteroids
    • 9.3.5. Others (NSAIDs, Cough suppressant, etc.)
  • 9.4. Market Attractiveness By Drug Class

10. Global Pneumonia Therapeutics Market Analysis and Forecasts, By Distribution Channel

  • 10.1. Introduction & Definition
  • 10.2. Key Findings / Developments
  • 10.3. Market Value Forecast By Distribution Channel, 2017-2031
    • 10.3.1. Hospital Pharmacies
    • 10.3.2. Retail Pharmacies
    • 10.3.3. Online Pharmacies
  • 10.4. Market Attractiveness By Distribution Channel

11. Global Pneumonia Therapeutics Market Analysis and Forecasts, By Region

  • 11.1. Key Findings
  • 11.2. Market Value Forecast By Region
    • 11.2.1. North America
    • 11.2.2. Europe
    • 11.2.3. Asia Pacific
    • 11.2.4. Latin America
    • 11.2.5. Middle East & Africa
  • 11.3. Market Attractiveness By Country/Region

12. North America Pneumonia Therapeutics Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast By Type, 2017-2031
    • 12.2.1. Bacterial Pneumonia
    • 12.2.2. Viral Pneumonia
    • 12.2.3. Fungal Pneumonia
  • 12.3. Market Value Forecast By Age Group, 2017-2031
    • 12.3.1. Children
    • 12.3.2. Adult
    • 12.3.3. Geriatric
  • 12.4. Market Value Forecast By Route of Administration, 2017-2031
    • 12.4.1. Oral
    • 12.4.2. Parenteral
    • 12.4.3. Others
  • 12.5. Market Value Forecast By Drug Class, 2017-2031
    • 12.5.1. Antibiotics
    • 12.5.2. Antiviral Drugs
    • 12.5.3. Antifungal Drugs
    • 12.5.4. Corticosteroids
    • 12.5.5. Others (NSAIDs, Cough suppressant, etc.)
  • 12.6. Market Value Forecast By Distribution Channel, 2017-2031
    • 12.6.1. Hospital Pharmacies
    • 12.6.2. Retail Pharmacies
    • 12.6.3. Online Pharmacies
  • 12.7. Market Value Forecast By Country, 2017-2031
    • 12.7.1. U.S.
    • 12.7.2. Canada
  • 12.8. Market Attractiveness Analysis
    • 12.8.1. By Type
    • 12.8.2. By Age Group
    • 12.8.3. By Route of Administration
    • 12.8.4. By Drug Class
    • 12.8.5. By Distribution Channel
    • 12.8.6. By Country

13. Europe Pneumonia Therapeutics Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast By Type, 2017-2031
    • 13.2.1. Bacterial Pneumonia
    • 13.2.2. Viral Pneumonia
    • 13.2.3. Fungal Pneumonia
  • 13.3. Market Value Forecast By Age Group, 2017-2031
    • 13.3.1. Children
    • 13.3.2. Adult
    • 13.3.3. Geriatric
  • 13.4. Market Value Forecast By Route of Administration, 2017-2031
    • 13.4.1. Oral
    • 13.4.2. Parenteral
    • 13.4.3. Others
  • 13.5. Market Value Forecast By Drug Class, 2017-2031
    • 13.5.1. Antibiotics
    • 13.5.2. Antiviral Drugs
    • 13.5.3. Antifungal Drugs
    • 13.5.4. Corticosteroids
    • 13.5.5. Others (NSAIDs, Cough suppressant, etc.)
  • 13.6. Market Value Forecast By Distribution Channel, 2017-2031
    • 13.6.1. Hospital Pharmacies
    • 13.6.2. Retail Pharmacies
    • 13.6.3. Online Pharmacies
  • 13.7. Market Value Forecast By Country, 2017-2031
    • 13.7.1. Germany
    • 13.7.2. U.K.
    • 13.7.3. France
    • 13.7.4. Italy
    • 13.7.5. Spain
    • 13.7.6. Rest of Europe
  • 13.8. Market Attractiveness Analysis
    • 13.8.1. By Type
    • 13.8.2. By Age Group
    • 13.8.3. By Route of Administration
    • 13.8.4. By Drug Class
    • 13.8.5. By Distribution Channel
    • 13.8.6. By Country/Sub-region

14. Asia Pacific Pneumonia Therapeutics Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast By Type, 2017-2031
    • 14.2.1. Bacterial Pneumonia
    • 14.2.2. Viral Pneumonia
    • 14.2.3. Fungal Pneumonia
  • 14.3. Market Value Forecast By Age Group, 2017-2031
    • 14.3.1. Children
    • 14.3.2. Adult
    • 14.3.3. Geriatric
  • 14.4. Market Value Forecast By Route of Administration, 2017-2031
    • 14.4.1. Oral
    • 14.4.2. Parenteral
    • 14.4.3. Others
  • 14.5. Market Value Forecast By Drug Class, 2017-2031
    • 14.5.1. Antibiotics
    • 14.5.2. Antiviral Drugs
    • 14.5.3. Antifungal Drugs
    • 14.5.4. Corticosteroids
    • 14.5.5. Others (NSAIDs, Cough suppressant, etc.)
  • 14.6. Market Value Forecast By Distribution Channel, 2017-2031
    • 14.6.1. Hospital Pharmacies
    • 14.6.2. Retail Pharmacies
    • 14.6.3. Online Pharmacies
  • 14.7. Market Value Forecast By Country/Sub-region, 2017-2031
    • 14.7.1. China
    • 14.7.2. Japan
    • 14.7.3. India
    • 14.7.4. Australia & New Zealand
    • 14.7.5. Rest of APAC
  • 14.8. Market Attractiveness Analysis
    • 14.8.1. By Type
    • 14.8.2. By Age Group
    • 14.8.3. By Route of Administration
    • 14.8.4. By Drug Class
    • 14.8.5. By Distribution Channel
    • 14.8.6. By Country/Sub-region

15. Latin America Pneumonia Therapeutics Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast By Type, 2017-2031
    • 15.2.1. Bacterial Pneumonia
    • 15.2.2. Viral Pneumonia
    • 15.2.3. Fungal Pneumonia
  • 15.3. Market Value Forecast By Age Group, 2017-2031
    • 15.3.1. Children
    • 15.3.2. Adult
    • 15.3.3. Geriatric
  • 15.4. Market Value Forecast By Route of Administration, 2017-2031
    • 15.4.1. Oral
    • 15.4.2. Parenteral
    • 15.4.3. Others
  • 15.5. Market Value Forecast By Drug Class, 2017-2031
    • 15.5.1. Antibiotics
    • 15.5.2. Antiviral Drugs
    • 15.5.3. Antifungal Drugs
    • 15.5.4. Corticosteroids
    • 15.5.5. Others (NSAIDs, Cough suppressant, etc.)
  • 15.6. Market Value Forecast By Distribution Channel, 2017-2031
    • 15.6.1. Hospital Pharmacies
    • 15.6.2. Retail Pharmacies
    • 15.6.3. Online Pharmacies
  • 15.7. Market Value Forecast By Country/Sub-region, 2017-2031
    • 15.7.1. Brazil
    • 15.7.2. Mexico
    • 15.7.3. Rest of LATAM
  • 15.8. Market Attractiveness Analysis
    • 15.8.1. By Type
    • 15.8.2. By Age Group
    • 15.8.3. By Route of Administration
    • 15.8.4. By Drug Class
    • 15.8.5. By Distribution Channel
    • 15.8.6. By Country/Sub-region

16. Middle East & Africa Pneumonia Therapeutics Market Analysis and Forecast

  • 16.1. Introduction
    • 16.1.1. Key Findings
  • 16.2. Market Value Forecast By Type, 2017-2031
    • 16.2.1. Bacterial Pneumonia
    • 16.2.2. Viral Pneumonia
    • 16.2.3. Fungal Pneumonia
  • 16.3. Market Value Forecast By Age Group, 2017-2031
    • 16.3.1. Children
    • 16.3.2. Adult
    • 16.3.3. Geriatric
  • 16.4. Market Value Forecast By Route of Administration, 2017-2031
    • 16.4.1. Oral
    • 16.4.2. Parenteral
    • 16.4.3. Others
  • 16.5. Market Value Forecast By Drug Class, 2017-2031
    • 16.5.1. Antibiotics
    • 16.5.2. Antiviral Drugs
    • 16.5.3. Antifungal Drugs
    • 16.5.4. Corticosteroids
    • 16.5.5. Others (NSAIDs, Cough suppressant, etc.)
  • 16.6. Market Value Forecast By Distribution Channel, 2017-2031
    • 16.6.1. Hospital Pharmacies
    • 16.6.2. Retail Pharmacies
    • 16.6.3. Online Pharmacies
  • 16.7. Market Value Forecast By Country/Sub-region, 2017-2031
    • 16.7.1. GCC Countries
    • 16.7.2. South Africa
    • 16.7.3. Rest of MEA
  • 16.8. Market Attractiveness Analysis
    • 16.8.1. By Type
    • 16.8.2. By Age Group
    • 16.8.3. By Route of Administration
    • 16.8.4. By Drug Class
    • 16.8.5. By Distribution Channel
    • 16.8.6. By Country/Sub-region

17. Competition Landscape

  • 17.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 17.2. Market Share Analysis By Company (2022)
  • 17.3. Company Profiles
    • 17.3.1. AstraZeneca
      • 17.3.1.1. Company Overview
      • 17.3.1.2. Financial Overview
      • 17.3.1.3. Product Portfolio
      • 17.3.1.4. Business Strategies
      • 17.3.1.5. Recent Developments
    • 17.3.2. Novartis AG
      • 17.3.2.1. Company Overview
      • 17.3.2.2. Financial Overview
      • 17.3.2.3. Product Portfolio
      • 17.3.2.4. Business Strategies
      • 17.3.2.5. Recent Developments
    • 17.3.3. AbbVie Inc.
      • 17.3.3.1. Company Overview
      • 17.3.3.2. Financial Overview
      • 17.3.3.3. Product Portfolio
      • 17.3.3.4. Business Strategies
      • 17.3.3.5. Recent Developments
    • 17.3.4. Teva Pharmaceutical Industries Ltd.
      • 17.3.4.1. Company Overview
      • 17.3.4.2. Financial Overview
      • 17.3.4.3. Product Portfolio
      • 17.3.4.4. Business Strategies
      • 17.3.4.5. Recent Developments
    • 17.3.5. Sumitomo Pharma Co., Ltd.
      • 17.3.5.1. Company Overview
      • 17.3.5.2. Financial Overview
      • 17.3.5.3. Product Portfolio
      • 17.3.5.4. Business Strategies
      • 17.3.5.5. Recent Developments
    • 17.3.6. Pfizer Inc.
      • 17.3.6.1. Company Overview
      • 17.3.6.2. Financial Overview
      • 17.3.6.3. Product Portfolio
      • 17.3.6.4. Business Strategies
      • 17.3.6.5. Recent Developments
    • 17.3.7. Sanofi
      • 17.3.7.1. Company Overview
      • 17.3.7.2. Financial Overview
      • 17.3.7.3. Product Portfolio
      • 17.3.7.4. Business Strategies
      • 17.3.7.5. Recent Developments
    • 17.3.8. Lupin Pharmaceuticals, Inc.
      • 17.3.8.1. Company Overview
      • 17.3.8.2. Financial Overview
      • 17.3.8.3. Product Portfolio
      • 17.3.8.4. Business Strategies
      • 17.3.8.5. Recent Developments
    • 17.3.9. Wockhardt Ltd.
      • 17.3.9.1. Company Overview
      • 17.3.9.2. Financial Overview
      • 17.3.9.3. Product Portfolio
      • 17.3.9.4. Business Strategies
      • 17.3.9.5. Recent Developments
    • 17.3.10. Innoviva, Inc.
      • 17.3.10.1. Company Overview
      • 17.3.10.2. Financial Overview
      • 17.3.10.3. Product Portfolio
      • 17.3.10.4. Business Strategies
      • 17.3.10.5. Recent Developments

List of Tables

  • Table 01: Global Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017-2031
  • Table 02: Global Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 03: Global Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Age Group, 2017-2031
  • Table 04: Global Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 05: Global Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 06: Global Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 07: North America Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017-2031
  • Table 08: North America Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 09: North America Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Age Group, 2017-2031
  • Table 10: North America Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 11: Europe Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017-2031
  • Table 12: Europe Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 13: Europe Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Age Group, 2017-2031
  • Table 14: Europe Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 15: Europe Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 16: Europe Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 17: Asia Pacific Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017-2031
  • Table 18: Asia Pacific Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 19: Asia Pacific Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Age Group, 2017-2031
  • Table 20: Asia Pacific Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 21: Asia Pacific Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 22: Asia Pacific Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 23: Latin America Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017-2031
  • Table 24: Latin America Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 25: Latin America Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Age Group, 2017-2031
  • Table 26: Latin America Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 27: Latin America Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 28: Latin America Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 29: Middle East & Africa Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017-2031
  • Table 30: Middle East & Africa Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 31: Middle East & Africa Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Age Group, 2017-2031
  • Table 32: Middle East & Africa Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 33: Middle East & Africa Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 34: Middle East & Africa Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

List of Figures

  • Figure 01: Global Pneumonia Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Global Pneumonia Therapeutics Market Value Share Analysis, by Type, 2022-2031
  • Figure 03: Global Pneumonia Therapeutics Market Value Share Analysis, by Bacterial pneumonia, 2022-2031
  • Figure 04: Global Pneumonia Therapeutics Market Value Share Analysis, by Viral Pneumonia, 2022-2031
  • Figure 05: Global Pneumonia Therapeutics Market Value Share Analysis, by Fungal pneumonia, 2022-2031
  • Figure 06: Global Pneumonia Therapeutics Market Attractiveness Analysis, by Type, 2023-2031
  • Figure 07: Global Pneumonia Therapeutics Market Value Share Analysis, by Drug Class 2022-2031
  • Figure 08: Global Pneumonia Therapeutics Market Value Share Analysis, by Antibiotics, 2022-2031
  • Figure 09: Global Pneumonia Therapeutics Market Value Share Analysis, by Antiviral Drugs, 2022-2031
  • Figure 10: Global Pneumonia Therapeutics Market Value Share Analysis, by Antifungal Drugs, 2022-2031
  • Figure 11: Global Pneumonia Therapeutics Market Value Share Analysis, by Corticosteroids, 2022-2031
  • Figure 12: Global Pneumonia Therapeutics Market Value Share Analysis, by Others, 2022-2031
  • Figure 13: Global Pneumonia Therapeutics Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 14: Global Pneumonia Therapeutics Market Value Share Analysis, by Age Group, 2022-2031
  • Figure 15: Global Pneumonia Therapeutics Market Value Share Analysis, by Children, 2022-2031
  • Figure 16: Global Pneumonia Therapeutics Market Value Share Analysis, by Adults, 2022-2031
  • Figure 17: Global Pneumonia Therapeutics Market Value Share Analysis, by Geriatric, 2022-2031
  • Figure 18: Global Pneumonia Therapeutics Market Attractiveness Analysis, by Age Group, 2023-2031
  • Figure 19: Global Pneumonia Therapeutics Market Value Share Analysis, by Route of Administration, 2022-2031
  • Figure 20: Global Pneumonia Therapeutics Market Value Share Analysis, by Oral, 2022-2031
  • Figure 21: Global Pneumonia Therapeutics Market Value Share Analysis, by Parenteral, 2022-2031
  • Figure 22: Global Pneumonia Therapeutics Market Value Share Analysis, by Others, 2022-2031
  • Figure 23: Global Pneumonia Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 24: Global Pneumonia Therapeutics Market Value Share Analysis, by Distribution Channel, 2022-2031
  • Figure 25: Global Pneumonia Therapeutics Market Value Share Analysis, by Hospital Pharmacies, 2022-2031
  • Figure 26: Global Pneumonia Therapeutics Market Value Share Analysis, by Retail Pharmacies, 2022-2031
  • Figure 27: Global Pneumonia Therapeutics Market Value Share Analysis, by Online Pharmacies, 2022-2031
  • Figure 28: Global Pneumonia Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 29: Global Pneumonia Therapeutics Market Value Share Analysis, by Region, 2022-2031
  • Figure 30: Global Pneumonia Therapeutics Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 31: North America Pneumonia Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 32: North America Pneumonia Therapeutics Market Value Share Analysis, by Type, 2022-2031
  • Figure 33: North America Pneumonia Therapeutics Market Attractiveness Analysis, by Type, 2023-2031
  • Figure 34: North America Pneumonia Therapeutics Market Value Share Analysis, by Drug Class, 2022-2031
  • Figure 35: North America Pneumonia Therapeutics Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 36: North America Pneumonia Therapeutics Market Value Share Analysis, by Age Group, 2022-2031
  • Figure 37: North America Pneumonia Therapeutics Market Attractiveness Analysis, by Age Group, 2023-2031
  • Figure 38: North America Pneumonia Therapeutics Market Value Share Analysis, by Route of Administration, 2022-2031
  • Figure 39: North America Pneumonia Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 40: North America Pneumonia Therapeutics Market Value Share Analysis, by Distribution Channel, 2022-2031
  • Figure 41: North America Pneumonia Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 42: North America Pneumonia Therapeutics Market Value Share Analysis, by Country, 2022-2031
  • Figure 43: North America Pneumonia Therapeutics Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 44: Europe Pneumonia Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 45: Europe Pneumonia Therapeutics Market Value Share Analysis, by Type, 2022-2031
  • Figure 46: Europe Pneumonia Therapeutics Market Attractiveness Analysis, by Type, 2023-2031
  • Figure 47: Europe Pneumonia Therapeutics Market Value Share Analysis, by Drug Class, 2022-2031
  • Figure 48: Europe Pneumonia Therapeutics Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 49: Europe Pneumonia Therapeutics Market Value Share Analysis, by Age Group, 2022-2031
  • Figure 50: Europe Pneumonia Therapeutics Market Attractiveness Analysis, by Age Group, 2023-2031
  • Figure 51: Europe Pneumonia Therapeutics Market Value Share Analysis, by Route of Administration, 2022-2031
  • Figure 52: Europe Pneumonia Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 53: Europe Pneumonia Therapeutics Market Value Share Analysis, by Distribution Channel, 2022-2031
  • Figure 54: Europe Pneumonia Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 55: Europe Pneumonia Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022-2031
  • Figure 56: Europe Pneumonia Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 57: Asia Pacific Pneumonia Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 58: Asia Pacific Pneumonia Therapeutics Market Value Share Analysis, by Type, 2022-2031
  • Figure 59: Asia Pacific Pneumonia Therapeutics Market Attractiveness Analysis, by Type, 2023-2031
  • Figure 60: Asia Pacific Pneumonia Therapeutics Market Value Share Analysis, by Drug Class 2022-2031
  • Figure 61: Asia Pacific Pneumonia Therapeutics Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 62: Asia Pacific Pneumonia Therapeutics Market Value Share Analysis, by Age Group, 2022-2031
  • Figure 63: Asia Pacific Pneumonia Therapeutics Market Attractiveness Analysis, by Age Group, 2023-2031
  • Figure 64: Asia Pacific Pneumonia Therapeutics Market Value Share Analysis, by Route of Administration, 2022-2031
  • Figure 65: Asia Pacific Pneumonia Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 66: Asia Pacific Pneumonia Therapeutics Market Value Share Analysis, by Distribution Channel, 2022-2031
  • Figure 67: Asia Pacific Pneumonia Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 68: Asia Pacific Pneumonia Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022-2031
  • Figure 69: Asia Pacific Pneumonia Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 70: Latin America Pneumonia Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 71: Latin America Pneumonia Therapeutics Market Value Share Analysis, by Type, 2022-2031
  • Figure 72: Latin America Pneumonia Therapeutics Market Attractiveness Analysis, by Type, 2023-2031
  • Figure 73: Latin America Pneumonia Therapeutics Market Value Share Analysis, by Drug Class, 2022-2031
  • Figure 74: Latin America Pneumonia Therapeutics Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 75: Latin America Pneumonia Therapeutics Market Value Share Analysis, by Age Group, 2022-2031
  • Figure 76: Latin America Pneumonia Therapeutics Market Attractiveness Analysis, by Age Group, 2023-2031
  • Figure 77: Latin America Pneumonia Therapeutics Market Value Share Analysis, by Route of Administration, 2022-2031
  • Figure 78: Latin America Pneumonia Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 79: Latin America Pneumonia Therapeutics Market Value Share Analysis, by Distribution Channel, 2022-2031
  • Figure 80: Latin America Pneumonia Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 81: Latin America Pneumonia Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022-2031
  • Figure 82: Latin America Pneumonia Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 83: Middle East & Africa Pneumonia Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 84: Middle East & Africa Pneumonia Therapeutics Market Value Share Analysis, by Type, 2022-2031
  • Figure 85: Middle East & Africa Pneumonia Therapeutics Market Attractiveness Analysis, by Type, 2023-2031
  • Figure 86: Middle East & Africa Pneumonia Therapeutics Market Value Share Analysis, by Drug Class, 2022-2031
  • Figure 87: Middle East & Africa Pneumonia Therapeutics Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 88: Middle East & Africa Pneumonia Therapeutics Market Value Share Analysis, by Age Group, 2022-2031
  • Figure 89: Middle East & Africa Pneumonia Therapeutics Market Attractiveness Analysis, by Age Group, 2023-2031
  • Figure 90: Middle East & Africa Pneumonia Therapeutics Market Value Share Analysis, by Route of Administration, 2022-2031
  • Figure 91: Middle East & Africa Pneumonia Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 92: Middle East & Africa Pneumonia Therapeutics Market Value Share Analysis, by Distribution Channel, 2022-2031
  • Figure 93: Middle East & Africa Pneumonia Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 94: Middle East & Africa Pneumonia Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022-2031
  • Figure 95: Middle East & Africa Pneumonia Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 96: Global Pneumonia Therapeutics Market Share Analysis, by Company, 2022